A multicenter, phase 2, open label study evaluating APR-246, a novel p53 reactivator, in combination with azacitidine for TP53 mutated AML or MDS post alloBMT is nearly complete with results anticipated in the coming year (NCT03931291) (84). Here, TP53 is linked to acute myeloid leukemia.